Adults with chronic disease may experience uncertainty and depression when coping with their illness. This study identifies degrees of uncertainty and depression, as well as factors associated with depression in people with Parkinson's disease. The 120 participants included patients who visited the neurology outpatient department of a tertiary hospital in Seoul and individuals who attended public events managed by the Korean Parkinson's Disease Association. The mean age of the sample was 65.01 and 50.8% of patients were men. The mean scores of uncertainty and depression, measured using the Mishel Uncertainty in Illness Scale and Short Form Geriatric Depression Scale were 99.03 and 6.73, respectively. Approximately 68% of participants scored above the cutoff score for depression. Multiple regression analyses showed that uncertainty, perceived health status, and fatigue were factors significantly associated with depression. Nurses should be aware of and address these factors and their effects in order to implement interventions to prevent depression in people with Parkinson's disease.
INTRODUCTION
Generally, adults can decide how to manage their health if they know the state of their disease. According to Mishel and Braden (1988) , uncertainty is a cognitive state that occurs when one cannot construct events well because certain diseases have many unknown factors causing confusion in the patients. Uncertainty is divided into four subcategories: (i) ambiguity from an unclear disease state; (ii) complexity because of complicated treatments; (iii) inconsistency as a result of frequent changes in disease information; and (iv) the unpredictability of an unknown prognosis (Mishel, 1988) . Studies on uncertainty have largely been conducted among patients with chronic diseases such as cancer and diabetes mellitus (Cha & Kim, 2012; Chon & Kang, 2014 ).
Parkinson's disease (PD) is a progressive and disabling neurological movement disorder. In a qualitative study by Hermanns (2011) , most patients with PD stated that life with PD was full of uncertainty, which some patients compared to "a voyage in a boundless ocean" because this illness has a declining trajectory with no cure. However, few published studies have addressed uncertainty in people with PD.
Parkinson's disease is most common in people aged 50 and over. As people age, the likelihood of developing the disease increases (Bae et al., 2013) . According to the National Health Insurance Service of Korea (2011) , the number of patients who received treatment for PD in Korea in 2009 was almost three times higher than it was in 2002. Further, the medical cost of PD in 2013 doubled compared with 2008 (National Health Insurance Service of Korea, 2014) . Considering the fact that the population is aging, the number of patients with PD and the medical costs of treatment are predicted to rise.
Symptoms of PD fall into motor and non-motor categories. Motor symptoms consist of postural instability, muscle rigidity, tremors, and bradykinesia. Non-motor symptoms include cognitive impairment, depression, fatigue, sleep disturbances, and autonomic dysfunctions (Müller et al., 2013) . Motor symptoms are generally referred to as representative symptoms of PD, but non-motor symptoms also frequently occur in people with PD (Van Laar & Jain, 2014) .
LITERATURE REVIEW
Uncertainty in PD is associated not only with the type, frequency, and severity of symptoms but also with treatment effects. Pharmacological management is the major approach to managing motor symptoms of PD. Although patients with PD take medication to alleviate motor symptoms, they are likely to experience significant adverse effects that may occur without warning. Dopaminergic drugs are prescribed for motor symptoms but have been reported to have an inconsistent efficacy period (i.e. the time before it wears off), and may cause dystonia or dyskinesia. Moreover, they can show the "on-off phenomenon," which refers to unpredictable potency. Because of these adverse effects, monoamine oxidase type-B (MAO-B) inhibitors, anti-cholinergic medications, and anti-viral medications are frequently prescribed. However, these drugs can also cause adverse effects. For example, MAO-B inhibitors may cause orthostatic hypotension, hypertension, or hallucination (Shin & Hendrix, 2013) . In addition, anti-cholinergic and anti-viral medication may cause impaired mental activities (Magennis et al., 2014) . The risk of drug non-compliance increases when adverse effects occur. For example, depending on current symptom levels, some patients with PD regulate their dosage without the advice of medical personnel, which can aggravate their motor symptoms (Shin et al., 2015) .
Another reason people with PD are likely to experience uncertainty is that non-motor symptoms of PD can occur without notice. Approximately 80% of people with PD experience mild to severe cognitive impairments. The risk of dementia is six times higher in people with PD (Emre et al., 2014) . In addition, 40-70% of patients with PD experience fatigue and 40-90% suffer sleep disturbances, including insomnia (Van Laar & Jain, 2014) . Medications relieving these symptoms may need to be prescribed (Müller et al., 2013) . However, adding medications increases the risk of drug interactions causing other unwanted symptoms, especially in older adults (Zurakowski, 2009) .
The most common non-motor symptom of PD is depression (Dissanayaka et al., 2011) . The prevalence rate of depression in people with PD is almost twice as high than in people without PD, and is reported to involve greater anxiety and suicidal impulses than in patients with non-PD-related depression (Wichowicz et al., 2006; Dissanayaka et al., 2011) . Moreover, people with PD with depression are more likely to feel helpless, and experience greater deterioration in cognitive function and motor symptoms than people with PD without depression (Bae et al., 2013) . Studies have found that people with PD with depression have lower medication adherence rates than people with PD without depression (Richy et al., 2013) . Therefore, it is necessary for healthcare professionals to manage depression as medication therapy is the primary treatment for PD. Antidepressants such as selective serotonin and serotoninnorepinephrine reuptake inhibitors are usually prescribed to treat depression in people with PD (Shin & Hendrix, 2013) .
Sleep disturbances and decreased activities of daily living can function as predictors of depression in patients with PD (Wichowicz et al., 2006; Dissanayaka et al., 2011; Bae et al., 2013) . Fatigue and perceived health status were identified as predictors of depression in patients with spondyloarthritis, a refractory chronic disease like PD (Meesters et al., 2014) . However, these two factors have not been identified as predictors of depression in people with PD to date.
PURPOSE
This study aims to identify degrees of uncertainty and depression in people with PD and factors associated with depression. Based on previous studies and a literature review regarding refractory chronic diseases, we hypothesized that uncertainty would be a predictor of depression in patients with PD. In studies of chronic obstructive pulmonary disease and lung cancer, researchers discovered that uncertainty was one of the factors associated with depression (Hoth et al., 2013; Kurita et al., 2013) .
METHODS

Design
A cross-sectional, descriptive survey method was used in this study.
Sample
Study participants were recruited from the neurology outpatient department of a tertiary hospital in Seoul and individuals who attended public events conducted by the Korean Parkinson's Disease Association from March 2015 to May 2015. Literate patients with PD aged 20 or over with the capacity to understand survey questions were included. Individuals were excluded if they had cognitive impairment or Mini-mental State Examination (MMSE) scores ≤ 24 (Folstein et al., 1975) .
Data collection
Three trained research assistants (RAs) approached approximately 150 people with PD, and a total of 123 consented to participate in the study. Each participant signed informed consent before data collection. Participants either completed a written survey or were interviewed by RAs if they required assistance because of tremors or visual problems. Each participant spent approximately 15 min completing the survey. A small gift was provided to each participant upon completion of the survey. After removing three incomplete questionnaires, 120 surveys were included in the final data analysis. The number of study participants was decided by the G*Power 3.1.3 program (Faul et al., 2009) . For a multiple linear regression model of seven independent variables (medication adherence, quality of sleep, fatigue, activities of daily living, instrumental activities of daily living, perceived health status, and uncertainty), for predicting one dependent variable of depression, at least 109 participants were needed with an effect size of 0.15 (d), power of 0.80 (1-β), and two-tailed level of significance of 0.05. The sample size (n = 120) was therefore considered sufficient to undertake this study.
Ethical considerations
The Institutional Review Board of the Yonsei University Medical Center, Seoul, South Korea (No. 4-2015-0027 ) approved this study. Participants' names and identifying information were not included on the survey questionnaires in order to ensure confidentiality. In addition, surveys were coded using numbers only, making survey responses anonymous. All data were stored in accordance with ethical policies, and only researchers were allowed to access participant data.
Measurements
Several standardized scales validated for use with Korean patients with PD and investigator-designed items were used. All standardized scales were used with permission.
Demographic characteristics
Sociodemographic data were collected including gender, age, marital status, living arrangements, educational level, employment status, monthly income, and religion.
Disease-related characteristics
Disease-related data were collected including disease period (i.e. duration in months), onset age, and experiences of falls (yes/no). Other disease-related data are as follows:
Medication adherence
The Korean version of the Modified Morisky Scale (MMS) was used to measure medication adherence (Case Management Society of Korea, 2007) . The Korean version was derived from the MMS, which was designed to evaluate motivation and knowledge regarding one's medications (Case Management Society of America, 2004) . This version includes six items with two subscales. The motivation subscale consists of three items to measure motivation to adhere to one's medication regimen, while the knowledge subscale includes three items to measure knowledge about one's medications. Each item is scored using a dichotomous scale of 0 (yes) or 1 (no). A total score of 2 or more on the motivation subscale is considered "high motivation" and a score of 2 or more on the knowledge subscale represents "high knowledge." Scores of 0 or 1 on the motivation or knowledge subscale represent "low motivation" or "low knowledge," respectively.
Quality of sleep
The Korean version of the Parkinson's Disease Sleep Scale (PDSS) was used to measure quality of sleep (Baik et al., 2005) . The Korean version was derived from the PDSS containing 15 items, with response options for each item ranging from 0 to 10 (Chaudhuri et al., 2002) . A higher score represents better sleep quality. The Cronbach's α in this study was 0.88.
Fatigue
The Korean version of the Parkinson Fatigue Scale (PFS-16) was used to measure fatigue. It originated from PFS-16, including 16 items with response options for each item ranging from 1 to 5 (Brown et al., 2005) . A higher score represents worse fatigue. The Cronbach's α in this study was 0.94.
Activities of daily living
The Korean version of the Schwab and England Activities of Daily Living Scale (SEADL) measured activities of daily living. It originated from SEADL, including only one question with responses ranging from 0% to 100% (Schwab & England, (Cho, 1998) . The Korean version of this scale was derived from the IADL, containing nine items, with responses to each item ranging from 0 to 2 (Fillenbaum, 1985) . The total score ranges between 0 and 18, with higher scores representing greater independence in instrumental activities of daily living. The Cronbach's α in this study was 0.84.
Perceived health status
Perceived health status was measured using a single item developed by the investigator. Participants were required to choose how they would rate their overall health among "good," "fair," and "poor."
Uncertainty
The Korean version of the Mishel Uncertainty in Illness Scale (MUIS) measured uncertainty in managing one's disease (Chung et al., 2005) . The Korean version of this scale was derived from the MUIS, containing 33 items, with response options for each item ranging from 1 to 5 (Mishel, 1988) . Total scores ranged between 33 and 165, with a higher score representing greater uncertainty. The Cronbach's α in this study was 0.84.
Depression
The Korean version of the Short Form Geriatric Depression Scale (SFGDS) measured depression (Cho et al., 1999) . The Korean version was derived from the 15-item SFGDS, with response options for each item ranging from 0 to 1 (Sheikh & Yesavage, 1986) . Total scores ranged between 0 and 15, with scores of 5 or above considered to indicate depression. The Cronbach's α in this study was 0.83.
DATA ANALYSIS
SPSS version 20.0 (IBM Corp, Armonk, NY, USA) was used for descriptive and inferential statistics. Descriptive analyses of the data were implemented for participants' demographic characteristics, disease-related characteristics, and the level of uncertainty and depression. We used two-sample t-tests, analyses of variance (ANOVA), Pearson's correlation coefficients, and multiple linear regression to analyze whether uncertainty and other characteristics were associated with depression. 
RESULTS
Depression by demographic characteristics
Men accounted for 50.8% (n = 61) of the 120 participants. The mean age was 65.01 (standard deviation [SD] = ±9.08) years. Participants with jobs accounted for 26.7% (n = 32). There were no significant differences in the SFGDS scores by demographic characteristics (Table 1) .
Depression by disease-related characteristics
The mean disease period was 85.55 (SD = ±75.17) months. The mean onset age was 57.94 (SD = ±11.88) years. The mean MMS score for motivation was 2.20 (SD = ±0.87), and for knowledge was 2.30 (SD = ±0.77). The mean PDSS and PFS-16 scores were 93.39 (SD = ±24.13) and 48.58 (SD = ±13.76), respectively. The mean SEADL score was 82.50% (SD = ±13.24). The mean IADL score was 15.93 (SD = ±2.73). Perceived Health Status including three categories was used to measure participants' general health condition; 8.3% (n = 10), 57.5% (n = 69), and 34.2% (n = 41) of participants indicated "good," "fair," and "poor," respectively. Statistically significant differences in SFGDS were determined using the MMS for motivation (t = 2.066, P = 0.041), PDSS (F = 5.329, P = 0.006), PFS-16 (F = 8.865, P < 0.001), SEADL (t = 2.218, P = 0.028), IADL (t = 2.379, P = 0.019), and Perceived Health Status (F = 12.960, P < 0.001) ( Table 2 ). Table 3 shows the value of uncertainty and depression as measured by the Korean version of the MUIS (Chung et al., 2005) and the SFGDS (Cho et al., 1999) , respectively. The mean MUIS score was 99.03 (SD = ±13.04), with total scores ranging from 63 to 132. Among the four subcategories of uncertainty, the mean score of the 13-item ambiguity, seven-item complexity, seven-item inconsistency, and five-item unpredictability subscales were 44.78 (SD = ±7.15), 17.73 (SD = ±3.11), 19.35 (SD = ±3.75), and 14.55 (SD = ±3.22), respectively. Meanwhile, MUIS was measured by disease period (F = 0.240, P > 0.05). The mean uncertainty score was 98.83 (SD = ±12.60) for patients with a disease period of under 60 months, 100.46 (SD = ±13.23) for those with a disease period 60-120 months and 97.60 (SD = ±13.81) for those with a disease period of over 120 months. In addition, MUIS was measured by gender (t = 1.044, P > 0.05) and age (t = 0.818, P > 0.05). The mean scores in men (n = 61) and women (n = 59) were 100.25 (SD = ±11.83) and 97.76 (SD = ±14.16), respectively. The means in participants aged under 65 years (n = 57) and those 65 or older (n = 63) were 99.42 (SD = ±13.36) and 98.67 (SD = ±12.83), respectively. There was no significant difference in MUIS score by disease period, gender, or age.
Uncertainty and depression
The mean SFGDS score was 6.73 (SD = ±3.91), with scores ranging from 1 to 14 points. Of the 120 participants, 67.5% (n = 81) had scores 5 or greater, which was the cut-off score for depression.
Relationships among uncertainty, depression, and disease-related characteristics Short Form Geriatric Depression Scale scores were positively correlated with MUIS (r = 0.464, P < 0.001), Perceived Health Status (r = 0.378, P < 0.001), and PFS-16 (r = 0.378, P < 0.001). SFGDS scores were negatively correlated with the MMS motivation subscale (r = À0.227, P = 0.013), PDSS (r = À0.343, P < 0.001), SEADL (r = À0.248, P = 0.006), and IADL (r = À0.263, P = 0.004). That is, the greater the level of uncertainty, perceived health status, and fatigue, the higher the degree of depression. In addition, the better the motivation for medication adherence, quality of sleep, activities of daily living, and instrumental activities of daily living, the lower the degree of depression (Table 4) .
Factors associated with depression
In order to understand the factors associated with depression, MUIS, Perceived Health Status, PFS-16, MMS for motivation, and IADL scores were used as independent variables in a multiple linear regression model. These variables were selected using two-sample t-tests, ANOVA, and Pearson's correlation coefficients. As seen in Table 4 , SEADL and IADL were strongly correlated (r = 0.874, P < 0.001). In addition, PDSS and PFS-16 were also correlated (r = À0.529, P < 0.001). Therefore, SEADL and PDSS were excluded from the multiple regression model because of a multicollinearity problem (Hair et al., 2009 ). The full results are shown by stepwise method (Table 5 ). The variance inflation factor values for the independent variables were between 1.086 and 1.197. As these values were much lower than the threshold value of 10, multicollinearity concern was minimal in the analyzed model (Hair et al., 2009) . According to this model, higher uncertainty (β = 0.326, P < 0.001) and fatigue (β = 0.218, P = 0.009) were associated with higher degrees of depression. In addition, "fair" perceived health status was related to lower depression when compared to "poor" perceived health status (β = À0.233, P = 0.004). people with PD uncertainty, perceived health status, and fatigue level explained as much as 31.8% of the variance in depression (R 2 = 0.318, adjusted R 2 = 0.300, F = 17.994, P < 0.001).
DISCUSSION
To the best of our knowledge, this study is one of the first to quantitatively assess uncertainty in adults with PD, and to examine the relationship with other factors for predicting depression. Uncertainty, perceived health status, and fatigue were strong predictors of depression in people with PD. The results from this study extend knowledge related to uncertainty in chronic diseases, and suggest that the average degree of uncertainty in people with PD as measured by the MUIS is higher than in cancer and diabetic patients with foot problems (Chung et al., 2005) . In this study, the mean uncertainty score was 99.03
(SD = ±13.04), compared with people with cancer with a mean score of 94.22 (SD = ±14.26) (Cha & Kim, 2012) and people with diabetes with a foot disorder who had a mean score of 97.34 (SD = ±11.55) (Chon & Kang, 2014) . The results indicate that uncertainty provided the strongest independent explanatory power for depression among the independent variables tested. The mean MUIS uncertainty scores in men (n = 61) and women (n = 59) were 100.25 (SD = ±11.83) and 97.76 (SD = ±14.16), respectively; however, this difference was not statistically significant. The mean MUIS scores in participants aged under 65 years (n = 57) and in those 65 or older (n = 63) were 99.42 (SD = ±13.36) and 98.67 (SD = ±12.83), respectively; however, this difference was also not statistically significant. Thus, PD is accompanied by high levels of uncertainty regardless of gender or age, and should be addressed throughout the disease process.
In previous studies, timing and methods were emphasized as two main elements for intervention that can be used in order to lessen uncertainty. Mishel et al. (2002) conducted a study of prostate cancer patients in which they emphasized that nurses should create strategies to lessen uncertainty in the early disease period, in turn helping to reduce uncertainty, although this can never be entirely alleviated during the disease period. In this study of people with PD, the mean uncertainty score was 98.83 (SD = ±12.60) for patients with a disease period of under 60 months, 100.46 (SD = ±13.23) for those with a disease period 60-120 months and 97.60 (SD = ±13.81) for those with a disease period of over 120 months. Although this result was not statistically significant, it is notable that the mean uncertainty score for those with a disease period under 60 months was higher than for those with a disease period over 120 months. This result suggests that although uncertainty exists regardless of disease stage, the initiation of interventions to combat uncertainty need to commence early and continue throughout the disease progress. Regular education and consultation methods can contribute to decreasing uncertainty. In a qualitative study of 16 people with PD, Shin et al. (2015) found that 81.3% did not adhere to their designated medication regimen. Because the main reason for this phenomenon was that patients were afraid of unexpected adverse effects, they emphasized that regular education and consultation regarding PD medications is necessary to lessen patients' fear of unknown adverse effects.
Perceived health status, categorized into "good," "fair," and "poor" was the second strongest predictor of depression. In order to improve the perceived health status of people with PD, interventions that can modify health should be recommended. An exercise intervention has shown beneficial effects on both motor and non-motor symptoms of PD (Bloem et al., 2015) . This included aerobic, resistance, and balance exercises. An aerobic exercise, especially walking, can be a relevant option in terms of accessibility. Previous studies have provided evidence of the specific therapeutic effect of walking on gait and balance, as well as on fatigue in people with mild to moderate PD (Bello et al., 2013; Uc et al., 2014) . As their symptoms improve, people with PD may perceive that their health status is better.
The final factor predicting depression in people with PD in this study was fatigue. Previous PD studies exploring factors that predict depression have rarely used fatigue as an independent variable. Dissanayaka et al. (2011) indicated that a poor quality of sleep was associated with depression. Comparing this previous outcome to our study, poor quality of sleep can be highly correlated with fatigue. Furthermore, people with PD may consider fatigue, which is likely to be derived from a poor quality of sleep or other factors, as a more severe predictor of depression rather than the sleep disturbance itself.
In this study, medication adherence was not included in the regression model, as it was not significantly associated with depression in bivariate analyses. Previous research has indicated that depression can affect medication adherence. Richy et al. (2013) reported that depression was a factor associated with medication adherence in a study of people with PD who took an average of 3.6 PD medications per day (n = 15,846, mean age = 73 years). Results showed that adherence dropped as patients became more depressed. Because we did not investigate how many doses of medication participants took per day, we were not able to directly compare this to our findings. However, the finding that higher depression was associated with lower medication adherence suggests that nurses need to alleviate depression in order to manage PD.
As uncertainty, perceived health status, and fatigue were identified as predictors of depression, future longitudinal studies would be beneficial for assessing the changes in depression in people with PD after administering interventions to manage these factors.
STUDY LIMITATIONS
There are several limitations in this study. First, participants were recruited using convenience sampling in limited venues. This may limit generalization of the study outcomes to a broader population of people with PD. Second, the majority of participants had a mild form of PD and could independently walk. This may explain the fact that activities of daily living, which were introduced as a factor associated with depression in previous studies, was not included in the final regression model predicting depression. Third, data collection was based on participants' self-reports, which may weaken objectivity. According to Hammarlund et al. (2012) , self-reports and physical examination results can present different perspectives of the same symptoms. Combining such methods can help researchers collect more complete and objective data. Therefore, it is recommended that future research use both self-reports and physical examination results when measuring motor and non-motor symptoms in people with PD.
Implications for nursing
Understanding the factors that are associated with depression in people with PD is important for the development of future interventions. Based on our study results, we recommend that nurses routinely assess uncertainty in people with PD. This step is important because uncertainty can predict depression in people with PD, and may lead to medication non-adherence with further negative consequences to health status. When designing uncertainty interventions, nurses should focus on characteristics that can alleviate uncertainty according to disease duration. In other words, if people with PD are newly diagnosed, their uncertainty may be derived from lack of information of PD itself. However, as time goes by, unexpected occurrence of the side effects of medication and non-motor symptoms can increase uncertainty levels.
It is also important for nurses to evaluate PD symptoms comprehensively, which means that they should focus on both motor and non-motor symptoms. In particular, screening for non-motor symptoms should be emphasized because nonmotor symptoms such as fatigue can predict depression.
CONCLUSION
The results suggest that uncertainty is common in people with PD, and the degree of uncertainty may be higher than that in patients with other chronic diseases, such as cancer and diabetes mellitus. Of the 120 participants, 67.5% reported a depressive mood. Our results indicate that uncertainty, perceived heath status, and fatigue are all factors associated with depression in people with PD. 
CONTRIBUTIONS
